Dietary agents as histone deacetylase inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cancer cells exhibit an imbalance in histone acetyltransferase (HAT) and histone deacetylase (HDAC) activity.
• HDAC inhibitors disrupt cancer cell cycles and induce apoptosis by derepressing genes like P21 and BAX.
• Potent HDAC inhibitors are sought for cancer therapy, but weaker ligands for cancer prevention are often overlooked.

Purpose of the Study:

• To explore the potential of dietary agents as HDAC inhibitors for cancer prevention.
• To differentiate between pharmacologic HDAC inhibitors and dietary HDAC inhibitors.
• To investigate the role of dietary HDAC inhibitors in modulating gene expression for cellular defense.

Main Methods:

• Review of existing literature on HDAC inhibitors and dietary agents.
• In vitro and in vivo studies of HDAC inhibitory activity of agents like butyrate, DADS, and SFN.
• Analysis of gene expression changes related to cell cycle and apoptosis.

Main Results:

• Butyrate, DADS, and SFN demonstrate HDAC inhibitory activity.
• Dietary HDAC inhibitors act as weak ligands, subtly regulating gene expression.
• Pharmacologic HDAC inhibitors potently derepress gene expression for therapeutic intervention.

Conclusions:

• Dietary agents can possess HDAC inhibitory properties, suggesting a role in cancer prevention.
• Weak HDAC inhibition by dietary compounds may offer a distinct approach to cancer chemoprevention.
• Further research is needed to understand how dietary HDAC inhibitors enhance normal cell responses to external stimuli.